Comparison of key steps in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in rodents

Pharmacology and Toxicology

Volumn 81, Issue 5, 1997, Pages 226-231

  Sundström, Erik ^a,b   Samuelsson, Eva Britt ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Division of Geriatric Medicine   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); CATECHOLAMINE; DOPAMINE RECEPTOR; NEUROTOXIN; NOMIFENSINE; NORADRENALIN; SELEGILINE;

ANIMAL MODEL; ARTICLE; BRAIN SYNAPTOSOME; CATECHOLAMINE NERVE CELL; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; TOXICOKINETICS;

ANIMALIA; GYMNOMYZA SAMOENSIS; RODENTIA;

EID: 0030680159     PISSN: 09019928     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0773.1997.tb00051.x     Document Type: Article

References (28)

1. Aiuchi, T., Y. Shirane, H. Kinemuchi, Y. Arai, S. K. Kim, K. Nakaya & Y. Nakamura: Effect of the tetraphenylboron ion on the inhibition of mitochondrial respiration in synaptosomes by the 1-methyl-4-phenylpyridinium ion (MPP+). Neurochem. Int. 1990, 17, 59-65.
2. Boyce, S., E. Kelly, C. Reavill, P. Jenner & C. D. Marsden: Repeated administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to rats is not toxic to striatal dopamine neurones. Biochem. Pharmacol. 1984, 33, 1747-1752.
3. Chiba, K., A. J, Trevor & N. Castagnoli, Jr.: Metabolism of the neurotoxic tertiary amin, MPTP, by brain monoamine oxidase. Bioehem. Biophys. Res. Commun. 1984, 120, 574-578.
4. +, metabolite of MPTP, by brain synaptosomes. Biochem. Biophys. Res. Comm. 1985, 128, 1228-1232.
5. Chiueh, C. C., S. P. Markey, R. S. Burns, J. N. Johannessen, A. Pert & I. J. Kopin: Neurochemical and behavioral effects of systemic and intranigral administration of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the rat. Eur. J. Pharmacol. 1984, 100, 183-194.
6. Davis, C. G., A. C. Williams, S. P. Markey, M. H. Ebert, E. D. Calne C. M. Reichert & I. J. Kopin: Chronic parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979, 1, 249-254.
7. Giovanni, A., B.-A. Sieber, R. Heikkila & P. K. Sonsalla: Correlation between the neostriatal content of the 1-methyl-4-pnenylpyridinium species and dopaminergic neurotoxicity following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration to several strains of mice. J. Pharmacol. Exp. Therap. 1991, 257, 691-697.
8. Giovanni, A., B.-A. Sieber, R. E. Heikkila & P. K. Sonsalla: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. J. Pharmacol. Exp. Therap. 1994a, 270, 1000-1007.
9. Giovanni, A., P. K. Sonsalla & R. E. Heikkila: Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Therap. 1994b, 270, 1008-1014.
10. Heikkila, R. E., L. Manzino, F. S. Cabbat & R. C. Duvoisin: Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311, 467-469.
11. Javitch, J.A., R. J. D'Amato, S. M. Strittmatter & S. H. Snyder: Parkinsonism-inducing neurotoxin, N-methyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc. Natl. Acad. Sci. U.S.A. 1985, 82, 2173-2177.
12. Kalaria, R. N., M. J. Mitchell & S. I. Harik: Correlation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity with blood-brain barrier monoamine oxidase activity. Proc. Natl. Acad. Sci. U.S.A. 1987, 82, 3521-3525.
13. Langston, J. W., P. Ballard, J. W. Tetrud & I. Irwin: Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219, 979-980.
14. Langston, J. W., I. Irwin & E. B. Langston: Pargyline prevents MPTP-induced parkinsonism in primates. Science 1984, 225, 1480-1482.
15. Martin, F. R., J. Sanchez-Ramos & M. Rosenthal: Selective and nonselective effects of 1-methyl-4-phenylpyridinium on oxygen consumption in rat striatal and hippocampal slices. J. Neurochem. 1991, 57, 1340-1346.
16. Nicklas, W. J., I. Vyas & R. Heikkila: Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985, 36, 2503-2508.
17. Nwanze, E., F. Souverbie, G. Jonsson & E. Sundström: Regional biotransformation of MPTP in the CNS of rodents and its relation to neurotoxicity. Neurotoxicology 1995, 16, 469-478.
18. Passonneau, J. V.: Fluorimetric method. In: Methods of enzymatic analysis. Ed: H.U. Bergmeyer. Academic Press, New York 1974, pp. 1468-1472.
19. + uptake in dopaminergic neurons of mouse: regional effects of MPTP neurotoxicity. Eur. J. Pharmacol. 1986, 126, 337-339.
20. Sonsalla, P. K. & R. E. Heikkila: Neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and methamphetamine in several strains of mice. Prog. Neuro-Psychopharmacol. & Biol. Psychiat. 1988, 12, 345-354.
21. Sonsalla, P K., S. K. Youngster, M. V. Kindt & R. E. Heikkila: Characteristics of 1-methyl-4-(2′-methylphenyl)-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the mouse. J. Pharmacol. Exp. Therap. 1987, 242, 850-857.
22. Stenström, A., E. Sundström & C. J. Fowler: Comparison of intra- and extrasynaptosomal monoamine oxidase-A and -B activities in the striatum and frontal cortex of two mice strains with different sensitivities to the neurotoxic actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Pharmacology & Toxicology 1989, 64, 276-281.
23. Sundström, E. & G. Jonsson: Pharmacological interference with the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in mice. Eur. J. Pharmacol. 1985, 110, 293-299.
24. Sundström, E., S. Kölare, F. Souverbie, E.-B. Samuelsson, H. Pschera, N.-O. Lunell & Á. Seiger: Neurochemical differentiation of human bulbospinal monoaminergic neurons during the first trimester. Dev. Brain Res. 1993, 75, 1-12.
25. Sundström, E., I. Strömberg, T. Tsutsumi, L. Olson & G. Jonsson: Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57 BL/6 mice: Comparison with three other strains of mice. Brain Res. 1987, 405, 26-38.
26. Vyas, I., R. E. Heikkila & W. J. Nicklas: Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenyrpyridinium. J. Neurochem. 1986, 46, 1501-1507.
27. 3-MPTP) is a more potent dopaminergic neurotoxin than MPTP in mice. Eur. J. Pharmacol. 1986, 122, 283-287.
28. + is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Exp. Neurol. 1994, 127, 54-61.